lycorine has been researched along with Idiopathic Parkinson Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, CZ; Chen, JY; Chen, Y; Lu, JH; Su, HX; Tan, JQ; Yuan, NN; Zhu, Q; Zhuang, XX | 1 |
1 other study(ies) available for lycorine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
Topics: alpha-Synuclein; Amaryllidaceae Alkaloids; Animals; Autophagy; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Humans; Male; Mice, Transgenic; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Phenanthridines; Proteasome Endopeptidase Complex; Rats; Ubiquitin; Up-Regulation | 2021 |